Scinai Immunotherapeutics Ltd
SCNI
View Detailed Chart
1.130USD
-0.140-11.02%
Close 11/04, 16:00（ET）Quotes delayed by 15 min
1.71MMarket Cap
0.46P/E TTM
Intraday
1m
30m
1h
D
W
M
D
Today
-11.02%
5 Days
-24.67%
1 Month
-15.04%
6 Months
-59.35%
Year to Date
-66.22%
1 Year
-69.04%
View Detailed Chart
TradingKey Stock Score of Scinai Immunotherapeutics Ltd
Currency: USD Updated: 2025-11-04Key Insights
The company's fundamentals are relatively stable. Its valuation is considered fairly valued,and institutional recognition is very high. The company shows very weak stock market performance, in line with its fundamentals and technicals. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Scinai Immunotherapeutics Ltd's Score
Support & Resistance
No Data
Score Analysis
Current score
Previous score
Analyst Rating
Based on
0
analysts
--
Current Rating
--
Target Price
--
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Scinai Immunotherapeutics Ltd Highlights
StrengthsRisks
Scinai Immunotherapeutics Ltd, formerly known as BiondVax Pharmaceuticals Ltd is an Israel-based biopharmaceutical company that is principally focused on developing, manufacturing, and commercializing medical products for the prevention and treatment of autoimmune and infectious diseases but also for other illnesses. The Company’s core focus is to develop NanoAbs for the treatment of various diseases such as COVID-19, psoriasis, and asthma. The Company's product NanoAb is based on alpaca-derived nanosized antibodies (NanoAbs), also known as VHH-antibodies. Additionally, the Company offers manufacturing facilities, aseptic fill and finish suites, laboratories, and experienced professionals for other research and development companies. Scinai Immunotherapeutics Ltd operates in Israel.
Growing
The company is in a growing phase, with the latest annual income totaling USD 658.00K.
Turnaround to Profit
The company's performance has turned profitable, with the latest annual net income of USD .
Overvalued
The company’s latest PE is 0.10, at a high 3-year percentile range.
Institutional Buying
The latest institutional holdings are 247.10K shares, increasing 46.05% quarter-over-quarter.
Lower Market Activity
The company has less investor interest, with a 20-day turnover ratio of -0.81.
Scinai Immunotherapeutics Ltd News
More news coming soon, stay tuned...
Financial Indicators
EPS
No Data
Total revenue
No Data
Scinai Immunotherapeutics Ltd Info
Scinai Immunotherapeutics Ltd, formerly known as BiondVax Pharmaceuticals Ltd is an Israel-based biopharmaceutical company that is principally focused on developing, manufacturing, and commercializing medical products for the prevention and treatment of autoimmune and infectious diseases but also for other illnesses. The Company’s core focus is to develop NanoAbs for the treatment of various diseases such as COVID-19, psoriasis, and asthma. The Company's product NanoAb is based on alpaca-derived nanosized antibodies (NanoAbs), also known as VHH-antibodies. Additionally, the Company offers manufacturing facilities, aseptic fill and finish suites, laboratories, and experienced professionals for other research and development companies. Scinai Immunotherapeutics Ltd operates in Israel.
Ticker SymbolSCNI
CompanyScinai Immunotherapeutics Ltd
CEOMr. Amir Reichman
Websitehttps://www.scinai.com/
Related Instruments
+1.15%
+0.32%
+1.85%
+0.38%
+0.93%
+1.66%
-1.75%
+0.13%
+0.78%
-1.46%
-1.88%
-1.02%
+2.61%
+1.01%
-0.93%
-0.64%
0.00%
-2.22%
-2.44%
-13.78%Popular Symbols
